AU2001244713A1 - Transporters and drug delivery system by using the same - Google Patents

Transporters and drug delivery system by using the same

Info

Publication number
AU2001244713A1
AU2001244713A1 AU2001244713A AU4471301A AU2001244713A1 AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1 AU 2001244713 A AU2001244713 A AU 2001244713A AU 4471301 A AU4471301 A AU 4471301A AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1
Authority
AU
Australia
Prior art keywords
transporters
same
delivery system
drug delivery
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244713A
Other languages
English (en)
Inventor
Mitsuaki Kuwano
Masaki Nakagawa
Hiroshi Suhara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AU2001244713A1 publication Critical patent/AU2001244713A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001244713A 2000-04-03 2001-04-03 Transporters and drug delivery system by using the same Abandoned AU2001244713A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-101113 2000-04-03
JP2000101113 2000-04-03
JP2001-56912 2001-03-01
JP2001056912 2001-03-01
PCT/JP2001/002882 WO2001074400A1 (fr) 2000-04-03 2001-04-03 Transporteurs et systeme de distribution de medicament les utilisant

Publications (1)

Publication Number Publication Date
AU2001244713A1 true AU2001244713A1 (en) 2001-10-15

Family

ID=26589355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244713A Abandoned AU2001244713A1 (en) 2000-04-03 2001-04-03 Transporters and drug delivery system by using the same

Country Status (7)

Country Link
US (1) US7455855B2 (de)
EP (1) EP1279406A4 (de)
KR (1) KR100777195B1 (de)
CN (1) CN100479862C (de)
AU (1) AU2001244713A1 (de)
CA (1) CA2404737C (de)
WO (1) WO2001074400A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
EP1437143A4 (de) * 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd Injektionen für augengewebe mit an polyethylenglykol gebundenem arzneimittel
US7279150B2 (en) * 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7495116B2 (en) 2002-03-29 2009-02-24 Nof Corporation Phospholipid derivative
WO2004029104A1 (ja) * 2002-09-30 2004-04-08 Nof Corporation リン脂質誘導体
ES2530776T3 (es) * 2003-01-06 2015-03-05 Nof Corp Derivados de fosfolípidos y proceso para su producción
US7399877B2 (en) * 2003-03-20 2008-07-15 Nof Corporation Phospholipid derivative
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2010074325A1 (en) 2008-12-25 2010-07-01 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US9572895B2 (en) 2010-08-06 2017-02-21 The Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3448389B1 (de) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Chinazolin- und indolderivate zur behandlung von medizinischen störungen
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
WO2021178920A1 (en) 2020-03-05 2021-09-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
FR2660193B1 (fr) * 1990-04-03 1994-11-04 Philippe Maincent Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
DE4120760A1 (de) 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
CA2137297C (en) * 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
AU704591B2 (en) * 1994-04-04 1999-04-29 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
JP3525516B2 (ja) * 1994-10-27 2004-05-10 日本油脂株式会社 反応性小胞体、小胞体修飾剤および製造方法
BR9610492A (pt) * 1995-09-21 1999-03-30 Andaris Ltd Veículos e intensificadores de transcitose para liberação de droga
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP2002513391A (ja) * 1996-11-05 2002-05-08 ザ チルドレンズ メディカル センター コーポレイション 血管形成の抑制のための方法と組成物
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
ATE245444T1 (de) 1998-02-09 2003-08-15 Enzon Pharmaceuticals Inc Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
ID28470A (id) 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
CZ303751B6 (cs) 1998-08-06 2013-04-24 Mountain View Pharmaceuticals, Inc. Farmaceutický prostredek urikasy, lécivo, pouzití a zpusob prípravy
IL143555A0 (en) * 1998-12-18 2002-04-21 Hadasit Med Res Service Method of administering a compound to multi-drug resistant cells
ATE400289T1 (de) 1999-02-08 2008-07-15 Human Genome Sciences Inc Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)
AU770390B2 (en) 1999-04-23 2004-02-19 Alza Corporation Releasable linkage and compositions containing same
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
CA2397016C (en) * 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
EP1437143A4 (de) * 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd Injektionen für augengewebe mit an polyethylenglykol gebundenem arzneimittel
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum

Also Published As

Publication number Publication date
CN100479862C (zh) 2009-04-22
US20030144247A1 (en) 2003-07-31
CA2404737A1 (en) 2001-10-11
EP1279406A4 (de) 2007-10-24
WO2001074400A1 (fr) 2001-10-11
CN1420790A (zh) 2003-05-28
CA2404737C (en) 2010-06-29
EP1279406A1 (de) 2003-01-29
KR20030009414A (ko) 2003-01-29
US7455855B2 (en) 2008-11-25
KR100777195B1 (ko) 2007-11-19

Similar Documents

Publication Publication Date Title
AU2001244713A1 (en) Transporters and drug delivery system by using the same
AU2001288388A1 (en) Substance delivery system
AU2123200A (en) Drug delivery device
EP1545662B8 (de) Verabreichungssystem für arzneien
AU4985600A (en) Drug delivery device
AU2001264887A1 (en) Drug delivery device
AU1719800A (en) Drug delivery systems and methods
AU2001238386A1 (en) Medication delivery devices
AU2002244142A1 (en) Integrated medication delivery system
AU7839900A (en) Reusable medication delivery device
AU2001235009A1 (en) Drug delivery apparatus
AU2463701A (en) Drug delivery system exhibiting permeability control
AU4947100A (en) Drug delivery device
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2001281171A1 (en) Medication dispensing system
AU4995100A (en) Selectable agent delivery system
AU2001270963A1 (en) Transdermal drug delivery system
AU3837999A (en) Drug delivery device
AU2001260244A1 (en) Product delivery system
AU6196600A (en) Medication reminder system
AU2002222138A1 (en) Drug delivery system
AU2003285550A1 (en) Drug delivery system
AU2001244854A1 (en) Local drug delivery
AU2002210580A1 (en) Drug delivery system
AU2983100A (en) Drug delivery vehicle